Consumer News: These breakfast cereals look healthy — but nutritionists say don't be fooled

New federal action targets concentrated compounds sold nationwide

• The Drug Enforcement Administration (DEA) plans to temporarily place 7-OH and three related substances into Schedule I of the Controlled Substances Act.

• The action focuses on highly concentrated, synthetic products not botanical kratom products that contain naturally occurring 7-OH below a specified threshold.

• Once the temporary scheduling takes effect, the manufacture, sale, distribution, and possession of covered substances will be subject to federal criminal, civil, and administrative laws.

The U.S. Drug Enforcement Administration (DEA) is taking action against a group of substances that officials say pose a growing threat to public safety.

On July 1, the agency announced that it has filed notices of intent to temporarily place 7-hydroxymitragynine (7-OH) and three related substances into Schedule I of the Controlled Substances Act.

Before making the move, the Department of Health and Human Services determined that synthetic 7-OH and the related substances have no accepted medical use and a high potential for abuse. According to the DEA, the temporary scheduling is intended to give law enforcement and public health agencies additional tools to respond to what it describes as an emerging threat.

Temporarily scheduling these substances underscores the emphasis this Administration has put on the safety, health and well-being of the American people, DEA Administrator Terrance Cole said in a news release.

This action gives law enforcement and public health partners the tools needed to address this emerging threat. We appreciate the FDA's scientific expertise and our continued partnership with HHS to address emerging threats, and we will continue to act aggressively when dangerous substances threaten Americans.

What the DEA is changing

The DEA submitted two separate Notices of Intent. One applies to 7-OH above a specified threshold, while the other covers three related substances: mitragynine pseudoindoxyl (MP), MGM-15, and MGM-16.

If the temporary scheduling orders take effect, the manufacture, distribution, sale, and possession of the covered substances will become subject to federal criminal, civil, and administrative penalties under the Controlled Substances Act.

The agency emphasized that this action is not aimed at all kratom products. Instead, it specifically targets synthesized products and products containing elevated concentrations of 7-OH above the threshold outlined in the scheduling order.

According to the DEA, naturally occurring 7-OH is present only in trace amounts in the Mitragyna speciosa plant, while laboratory testing has found that many commercial products contain much higher concentrations.

Officials also noted that products containing semi-synthetic 7-OH have become increasingly common online and in gas stations, convenience stores, and smoke shops, where they're sold as powders, capsules, tablets, gummies, and dissolvable strips.

What this means for consumers

For consumers, the biggest takeaway is that the DEA's announcement does not apply to every botanical kratom product. The agency says the temporary scheduling is directed at synthesized products and those with elevated levels of 7-OH that exceed the specified threshold.

If the temporary scheduling takes effect, products covered by the order would become subject to the same federal restrictions that apply to other Schedule I controlled substances. That means their manufacture, sale, distribution, and possession would be prohibited under federal law.

The DEA says the move is part of a broader effort to address the opioid epidemic and protect the public from dangerous synthetic drugs that it believes present unpredictable risks.

New research finds weight-loss drug could influence energy use in unexpected ways

• A new clinical trial suggests tirzepatide may activate brown fat, a type of fat that burns calories to produce heat.

• Researchers used advanced imaging before and after 24 weeks of treatment to measure changes in brown fat activity.

• The findings suggest tirzepatide may affect both appetite and how the body uses energy, though more research is needed.

Tirzepatide has become well known for helping people lose weight by reducing appetite and making it easier to eat smaller portions. But new research presented at ENDO 2026, the Endocrine Society's annual meeting, suggests the medication may have another effect happening behind the scenes.

Researchers found evidence that tirzepatide activates brown adipose tissue, often called brown fat. Unlike the more familiar white fat, which stores energy, brown fat burns calories to produce heat.

Scientists have known for years that adults have brown fat, but it tends to be much less active in people with obesity. Until now, exposure to moderate cold temperatures has been considered its strongest known activator.

The new findings raise the possibility that tirzepatide doesn't simply help people eat less it may also influence how the body expends energy. According to the researchers, this represents an important step toward understanding the medication's full range of effects.

How the researchers studied brown fat

To investigate the question, researchers conducted a randomized, placebo-controlled clinical trial involving premenopausal women with obesity.

Participants underwent specialized imaging before starting treatment and again after 24 weeks. The research team used cold-stimulated PET/CT scans along with MRI imaging to evaluate both the activity and volume of brown adipose tissue.

In the trial, we asked a different question: beyond eating less, does tirzepatide also change how the body burns energy specifically through brown adipose tissue, a metabolically active type of fat that produces heat and consumes calories? researcher Rok Herman, M.D., said in a news release.

The team also examined whether there were signs that white fat beneath the skin might begin taking on characteristics of more metabolically active "beige" fat, which shares some properties with brown fat.

What the results could mean

After 24 weeks, the researchers found that tirzepatide significantly increased both the activity and volume of brown adipose tissue.

The percentage of participants with PET/CT-detectable brown fat activity rose from 41.2% before treatment to 64.7% afterward, while the placebo group did not experience a similar change. The imaging also suggested possible signs that some white fat was becoming more like calorie-burning beige fat.

The researchers say these findings add another piece to the puzzle of how newer anti-obesity medications work. Rather than acting only as appetite suppressants, tirzepatide may also influence energy expenditure at the tissue level.

This adds a new layer to how we understand the new generation of anti-obesity medications, Dr. Herman said. They are not only appetite suppressants tirzepatide also appears to modulate energy expenditure at the tissue level, opening a plausible path toward future therapies that combine appetite regulation with thermogenic activation.

They caution that additional research is needed, but believe future studies could explore whether targeting brown and beige fat activity might become part of a more tailored approach to obesity treatment.

Large study suggests inherited genetics play a bigger role than expected

• A study of more than 86,000 children found that the link between parents' and children's BMI is largely explained by shared genetics.

• Researchers found little evidence that a mother's BMI during pregnancy has a major effect on a child's risk of obesity later in childhood beyond inherited genes.

• The findings don't mean childhood obesity is inevitable, as environment and lifestyle still influence how genetic risk is expressed.

If obesity tends to run in families, is it because children inherit their parents' habits, or because they inherit their parents' genes? A new international study suggests genetics account for much of the connection between parents' body weight and their children's weight during early childhood.

Researchers say higher body mass index (BMI) in parents has long been linked with higher BMI in their children, but it's been difficult to determine whether that relationship is driven by pregnancy-related biological effects, family environment, or inherited genetics. Understanding the answer could help shape future approaches to preventing childhood obesity.

The researchers note that maintaining a healthy weight remains important for many reasons, particularly during pregnancy. However, their findings suggest that reducing a parent's BMI before conception alone may not substantially lower a child's likelihood of developing obesity later in childhood.

Obesity runs in families, but it is difficult to work out why this is, researcher Dr. Tom Bond said in a news release.

Our results suggest that the link between a mother's or father's body mass index and their children's BMI up to age 8 is mostly due to inherited genes. Expectant parents should be encouraged to maintain a healthy weight, but this may not be enough to ensure that their children also have a healthy weight.

Looking at more than 86,000 families

For the study, researchers analyzed data from the Norwegian Mother, Father and Child Cohort Study, a large, long-running project that followed children born between 1999 and 2009.

The analysis included approximately 86,000 children. Researchers examined information on parents' BMI, children's birth weight, and children's BMI from 6 months through 8 years of age. They also looked at appetite-related eating behaviors when the children were 8 years old, including food responsiveness and emotional overeating.

Rather than simply comparing parents and children, the research team used statistical modeling to estimate how much of the relationship between parental BMI and childhood BMI could be attributed to shared genetics versus other possible influences, such as conditions during pregnancy.

They also explored whether maternal BMI during pregnancy affected birth weight and later childhood obesity risk.

What the researchers found

The results suggest that inherited genetics explained an estimated 79% of the statistical association between mothers' BMI and their children's BMI at age 8, and about 94% of the association between fathers' BMI and their children's BMI.

The researchers also found that higher parental BMI was associated with obesity-related eating behaviors in children, although they said they could not determine exactly how much of those behaviors were influenced by genetics.

Maternal BMI during pregnancy did appear to affect babies' birth weight, but researchers found little evidence that it had a large impact on a child's risk of obesity later in childhood beyond the genes passed from parent to child.

The researchers emphasize that these findings should not be interpreted to mean a child's future weight is predetermined. They note that children who inherit a genetic tendency toward a higher BMI may still experience different outcomes depending on their environment and lifestyle. They also stress that maternal obesity remains an important health concern because it is associated with other pregnancy and birth complications for both mothers and babies.

Users also report changes in what they buy

By Mark Huffman of ConsumerAffairs

• A growing number of people taking GLP-1 weight-loss medications are spending significantly less on groceries, according to new research from Worldpanel by Numerator.

• The study estimates households with a GLP-1 user spend about $570 less on groceries each year, contributing to an estimated $1.1 billion reduction in annual grocery spending across Britain.

• The findings suggest the drugs are beginning to reshape consumer buying habits, posing new challenges and opportunities for food manufacturers and retailers.

People use GLP-1 drugs such as Wegovy and Mounjaro to lose weight. But in many cases, as their waistline shrinks, their bank account grows.

According to a study by Worldpanel by Numerator, households that include someone taking a GLP-1 medication spend an average of about $570 less on groceries each year than households without a user. The British study estimates that across the United Kingdom, this translates into around $1.1 billion less annual grocery spending.

The research found that nearly 1.9 million adults in Britain are now using GLP-1 medications, almost three times as many as two years ago. About 6.3% of British households now include at least one user, underscoring how quickly the drugs have entered the mainstream.

The medications, originally developed to treat type 2 diabetes, work by mimicking the GLP-1 hormone, helping people feel full longer and reducing appetite. They have become increasingly popular for weight management because many users experience significant weight loss while taking them.

Changes in what people buy

Worldpanel by Numerator found the medications are changing what consumers buy as well as how much they spend. More than three-quarters of users reported eating less chocolate and fewer potato chips, while over half said they experienced fewer food cravings overall. Many also said they were eating more mindfully and choosing healthier foods.

The shift is beginning to ripple throughout the grocery industry.

Manufacturers and retailers are seeing weaker demand for traditional snack foods and confectionery, while interest is growing in products that are higher in protein and fiber or specifically marketed to GLP-1 users. Some supermarket chains have already introduced meal plans and products designed for consumers taking the medications.

The study also found that cost remains a significant barrier. About 40% of people who stopped taking GLP-1 medications said expense was the primary reason they discontinued treatment.

The findings are consistent with other recent research showing that GLP-1 medications are changing consumer spending habits. A peer-reviewed study published in the Journal of Marketing Research found that grocery spending falls by about 5.3% within six months after a household member begins taking a GLP-1 drug, with restaurant spending also declining.